Spring Pharmaceutical Group Financials

Spring Pharmaceutical Stock Summary

Spring Pharmaceutical competes with Suburban Propane, Pinterest, Agiliti, Kaltura, and National Rural. Spring Pharmaceutical Group, Inc., through its subsidiaries, engages in the research, development, manufacture, and sale of Chinese medicines primarily made from ginseng leaves extract in the Peoples Republic of China. Spring Pharmaceutical Group, Inc. was incorporated in 1989 and is based in Sishui, the Peoples Republic of China. China Yct is traded on OTC Exchange in the United States.

Spring Pharmaceutical Key Financial Ratios

Generally speaking, Spring Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from Spring Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of Spring Pharmaceutical over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Spring Pharmaceutical reports annually and quarterly.

Spring Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Spring Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Spring Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Spring Pharmaceutical competition to find correlations between indicators driving Spring Pharmaceutical's intrinsic value. More Info.Spring Pharmaceutical Group is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies reporting about  0.82  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Spring Pharmaceutical Group is roughly  1.22 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Spring Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Spring Pharmaceutical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spring Pharmaceutical's earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

If you are still planning to invest in Spring Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spring Pharmaceutical's history and understand the potential risks before investing.